# FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

> **NCT00769522** · PHASE3 · COMPLETED · sponsor: **German CLL Study Group** · enrollment: 564 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** Rituximab
- **DRUG:** Bendamustine
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT00769522
- **Lead sponsor:** German CLL Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-02
- **Primary completion:** 2011-07
- **Final completion:** 2018-01
- **Target enrollment:** 564 (ACTUAL)
- **Last updated:** 2024-12-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00769522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00769522, "FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00769522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*